Protokoly_diagnostiki_i_lechenia_zabolevany

II. "$ H.pylori: &,

III. " :

1.: " ( & , & ), ;

2.@ : " ( & ), .

IV. " % % :

1.7 " : , " , 3 , " , " , ;

2." : , ( , " , " ). V. $# % :

, , % .

VI. ' & $, ( &, )

VII. * : , " , " , -3 "-" ( ).

" : " ".

* :

1.H.pylori;

2.& ;

4.;

5.+ '!;

6.$# ;

7.;

8.% &;

9.D ;;

10." % &.

" : , 3 % .

" :

1.( , ),

2." ,

3.3 & " .

5 :

1._7 @!;

2.?J;, ?!;, ;

3.&

2.% " ( , % , % , % - );

3." ;

4.3 " " % @ ( , , , 3 , , . .);

5." H.pylori.

" & :

1.# (Er, Hb, L, , ! 7) ;

2.# " ;

3.;

4.H)B $ ;

5.7 ;

6.@ H.pylori ( & , HpSA , IgG + , ,-) ;

7.& ;

8.& .

" & & :

1.7 ;

2." ;

3.! " +- D ; - ( ) ;

4." Fe ;

5.;

6.7 3 ;

7.3 ;

8.B % " ;

9." D ; .

+ :

& % , " ! ,. .

3. $ $ &$

" 18 " , " " &% . , B $ & &$.B /7/ , " B ,# " " /8/. ; &% " " B ,$# 450 /8/.

; - .

B ( * * 20 ., 30 ,

( ) & $"

.:

1.> & " $ 3 , & [ .

2.> & 3 , 3 " , " " & " ( , ).

3.> & , " 3 ,& " & & +. pylori & - .

4.& " " " $& , $.

$ « ».

! &$ % & , & 3 % " ( ) 102-3 &. — (6 , ? &, _ $&),( & , -, , & ), " >1( ), " ( , ),(6 , ). % & & " -

>@ 3 " 2 &.

" -& $ $"$ : *, ,3 & 40 -60 . # "&,. 10-14 .

" & & :

1.10 % ; 1 ., 10 " ;

2.*6 250 .; 0,5 100 ;

3.* 4500 >@, ;

4.200 .

1." & : . . / B.+.@ ,

2.'.B. , .6.G . – 6.: 7 ;? -6>@, 2001. – 1248 .: .

3.@ & . >% " . – 6 – 6 ! , 2003.

4.Gastritis. Philadelfia: Intracorp, 2005.

5.6.M.@ . " 3 .-6, 1999.

6.@ 3 / . ?.?.< – 6.2002, 592 .

7.Kawacami Y., Akahane T., Yamaguchi M. et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thiother derivative alone and in combination with other antimicrobials againts recent clinical isolates of H.pylori. Antimicrob Agents Chemother, 2000. vol.44, N2.- P.458-461.

8.H. Holtmann, P. Bytzer, M. Metz, V. Loeffler. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease/ Aliment Pharmacol Ther 2002; 16: 479-485

* – , # (% % )

<

: 07-075

"$ &: "

:

& ! :

1.,

2.,

3." .

' & & ( ): 14

(:

K81 G

K81.1 G "

K83.0 G

K91.5 3 "

) : < – 3 " & %% " .

$ :

1."$: , " , $# ;

2.: & , , ;

3.: , , .

* :

1.% &;

2.% " ;

3.% " ;

4.- , +, % " ;

5." " " ;

6.& .

" :

" :

1.% ;

2." ( 3 ) .

5 :

1.H)B $ ;

2.# ;

3.?J;, ?!;, ;

4., 3 .

2.% & « » , , ;

3. H)B – # % " 2 , "" 52 , " & 3 , %- (6 % % " , ' , 1998).

" & :

1.H)B $ ;

2.# (6 ) ;

3.# " ;

4.?!;;

5.?J;;

6.;

7.B $;

8.& ;

9.& ;

10.@ & ;

11.< " % " .

" & & :

1.7 ;

2.G ;

3.;

4.# " ;

5.;

6.G ( &$, - ) ;

7.;

8.7 .

+ :

1.@ .

2.& .

3.6 " .

4..

5.D " .

) " " : & $ % " ; & $; & & % " . @% " &$ &

* 240-480 2 . ; % & " * & 250-500 2 , * 250-500 2 ,

-& % " #- 0,25-1,0 / 3-4 & 20-30 . % & &$ 3 ;

-D " – * 1-2 3 & , & *, % & & 3 &, " -( , $# ), % & & 3- &. ! &$ % % " ,% " , " & * " 10 / 1 & "& " 14 -20 .

-3 " % " % " * 10

000 >@ 3 " 2 &.

- ? +6 *, ( $# )1,5-2 " .

< & %$ $, % " " , . . 40% & $ " , .

" & :

1. *? 250 .; 250 , 500 ; 500 , 1000V ; 125/5 ;

2. *7 250 , 500 .; 250 /5 & ; 3. *_0,5 ; 4. *250 , 500 .;

5. *6 250 ; 0,5 100 ;

6.*B & 150 – 10 \ .

7.*@ 10 .;

8.*_, .;

9.*6 & 25% 20 .;

10.* 4500 >@ ;

11.? + 15 ;

12. * 250 .; 125 & ;

13.- 240, 480 ;

14.*6 100 % & .

" & & :

1.250 .;

2.*/ 250 , 500 .; 200 /100 , ; 3.*H 250 , .

4.! .

,- ! : ," .

/ , & :

1 " & : . . / B.+.@ ,

'.B. , .6.G . – 6.: 7 ;?-6>@, 2001. – 1248 .: .

2. " + " " : B.+.@ , M.J. K " – 6.: 7 ;?-6>@, 2004. – 1184 .: . ( «@ & 6 ») 3.Society of Nuclear Medicine Procedure Guideline for Hepatobiliary Scintigraphyversion 3.0, approved June 23, 2001SOCIETY OF NUCLEAR MEDICINE PROCEDURE GUIDELINES MANUAL MARCH 2003

4. EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF CHOLECYSTITIS Domingo S. Bongala, Jr., MD, FPCS, Committee on Surgical Infections, Philippine College of Surgeons, Epifanio de los Santos Avenue, Quezon City, Philippines

* – , # (% % )

<

: 07-075

"$ &: " :

& ! :

1.% - ;

2., " ;

3." .

' & & ( ): 14

(:

K86.0 G " & 3

K86.1 @ "

K86.2 % " %

K86.3 J % % " %

K86.8 @ " % " %

K86.9 < & % " % "

) : < (G ) - &- % " % # 6 $#& " &$.

$ : ( . '. " )

' 3 " " $# :

1.%$— " " ;

2."$ — $# , ;

3.% — , % , % ;

4.& $ % " % :

) — , , , & " ; ) — , ;

5. % — % , , , . .;

6.$# — &, , , , 3 , , " .

* :

1.;

2." % &;

3.% ;

4.;

5.– 3 " , , ,, , Mycoplasma;

6.& ;

7.pancreas: % , #

, 6- , . , , 3 ,

1.% ;

2.;

3." ;

4. 3 & " .

5 :

1.# (6 );

2.?J;, ?!;, ;

3.# " ;

4.;

5.$;

6.;

7.H)B $ .

3.;

4." .

" & :

1.# (6 );

2.# " ;

3.?!;;

4.?J;;

5.;

6.& 3-1 ( );

7." ;

8.B $;

9.$;

10.;

11.$;

12.H)B $ ;

13.7 ;

14.& ;

15.& .

" & & :

1.G ( &$, - );

2.;

3.D ;;

4.! ;

5..

+ :

1.@

2.! "

3.?

4.&

5.) &

J " .

% % & # .& # ,$ . @ " % , " % , & $" 3 #